Cdk2/9 Inhibitor; 507487-89-0; [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-PHENYL)-AMINE; 2L9NBR9W3T; 4-methyl-5-[2-(3-nitroanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; UNII-2L9NBR9W3T; CHEMBL298445; CK7; 2-Pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-; 4-(2-Amino-4-methyl-5-thiazolyl)-N-(3-nitrophenyl)-2-pyrimidinamine; (4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl)-(3-nitro-phenyl)-amine; 4-Methyl-5-(2-((3-nitrophenyl)amino)pyrimidin-4-yl)-1,3-thiazol-2-amine; 1pxo; 4-methyl-5-{2-[(3-nitrophenyl)amino]pyrimidin-4-yl}-1,3-thiazol-2-amine; 2wev; CDK Inhibitor, 1; 2c5p; Cdk2/9; (4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl)-(3-nitrophenyl)amine; BDBM8061; SCHEMBL1368256; DTXSID30332265; HMS3229D17; EX-A6806; BDBM50229973; ZINC03942776; DB02833; HY-103646; CS-0028810; 2-Anilino-4-(thiazol-5-yl)pyrimidine deriv. 32; Q27093793; 4-methyl-5-(2-(3-nitrophenylamino)pyrimidin-4-yl)thiazol-2-amine; [4-(2-Amino-4-methylthiazol-5-yl)pyrimidin-2-yl](3-nitrophenyl)amine; 2-[[3-Nitrophenyl]amino]-4-(2-amino-4-methylthiazole-5-yl)pyrimidine; 4-(2-amino-4-methylthiazol-5-yl)-N-(3-nitrophenyl) pyrimidin-2-amine; 4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-(3-nitrophenyl)pyrimidin-2-amine, 4